Explore Beth Heredia's board "Cannabus Oil Saves Lives" on Pinterest. Vitamin Weed': Neuroscientist says cannabis oil slows down aging process .. A Users' Guide | Cannabis To Palliate Stress And Anxiety Brain The Folks At Senior Centers Are Using A Lot Of Marijuana — The . Jordan Hancock. I spoke with cannabis artist Marty Klein of Easthampton and medical marijuana Growing Your Own Weed In Massachusetts: A How-To Guide or whatever you call the bud bits and kief, for making cannabis butter or oil later. If you did your grow right, and have a lot of funky people in your life, your. Evolution of Essential Oil in Domesticated Cannabis Odor and Other .. Up to a century ago, most people lived on farms and were well acquainted . The term “inflorescence” refers to 1 2 Cannabis: A Complete Guide FIGURE as 11, BC in some places (Hancock ), is the foun- dation of civilization.
For Hancock, Folks Hemp Oil Living In Wisconsin Guide CBD
Zacks Small-Cap Research analyst John Vandermosten reviewed the Q2 FY18 financial results for this epigenetics firm, which is moving forward with a Phase 3 trial targeting heart disease. Jason Kolbert, an analyst with Maxim Group, described the study, which enables this biotech's device to be used in patients undergoing heart surgery and will measure its effectiveness in reducing a common post-surgical side effect. David Kideckel, an analyst with Beacon Securities Ltd.
Andrew Fein, an analyst with H. A technical analysis by Clive Maund on CliveMaund. Ed Arce, an analyst with H. A regenerative therapy company with expertise in both cell therapy development and manufacturing, and a potential treatment for diabetes, differentiates this company, says Hunter Diamond, CFA, CEO of Diamond Equity Research.
This biotech reported positive results in a Phase 1b trial for its ovarian cancer immuno-oncology drug-delivery candidate, prompting increases in share price targets from a pair of analysts.
Maxim Group analyst Jason Kolbert discussed what the launch of a clinical trial in China means for this developer of immuno-oncology therapies. Michael Sheikh, the founder of Falcon Strategic Research, delves into a biotech company whose trial results he believes could fuel takeover speculation. After attending a conference on the latest in development of Alzheimer's disease treatments, Andrew Fein, an analyst with H.
Following the company's release of its latest financial report, three analysts weighed in on the results. Douglas Loe, an analyst with Echelon Wealth Partners, provided an update on this biotech's platform pipeline targeting ovarian and blood cancers, as well as respiratory syncytial virus.
This immunotherapy firm's stock recently doubled its Nov. Jason Kolbert, an analyst with Maxim Group, provided an update on this biopharmaceutical firm's two recently acquired oncology assets. Wedbush analyst Robert Driscoll provided an update on the lead asset of this drug developer targeting cancer. Medical Technology Stock Letter editor John McCamant outlines the reasons behind the buy rating and target price increases for a company that, in addition to developing an alternative to addictive opioids for pain relief, has candidates targeting multiple immune disorders and cancer.
Some tonnes of marijuana a year are up for grabs as Canada moves to legalize weed, says Rick Mills, founder of Ahead of the Herd, who puts forth his case on why cannabis stocks should be in every investor's portfolio. Analyst Kevin DeGeeter, with Ladenburg Thalmann, relayed the highlights from his recent meeting with this company's management team about near-term clinical news and pipeline plans.
Analyst Ed Arce discussed the rationale behind H. Maj Soueidan, cofounder of GeoInvesting, profiles his long history with a company providing medical devices for the home care market. John McCamant, editor of the Medical Technology Stock Letter, initiated coverage on a company that he calls an emerging leader in women's health.
An analysis of this company's quarterly update highlights a pipeline studded with candidates targeting neurological indications. Neil Maruoka, an analyst with Canaccord Genuity, provided an update on this biotech's progress through the regulatory approval process for one of its therapeutics. Mackie Research reported on this company's recent announcement about one of its product candidates targeting Alzheimer's disease. Analyst David Nierengarten with Wedbush explained the rationale for adding this biotech to his coverage universe.
With multiple candidates in the pipeline advancing through clinical trials, Ram Selvaraju, an analyst with H. The rapid increase in the incidence of chronic diseases and the need to reduce healthcare costs have led to the growth in telemedicine, and Reliq Health Technologies is adding thousands of patients to its rolls.
Analyst Russell Stanley with Echelon Wealth Partners explained the significance of the recent licensing agreement signed by this Canadian medical marijuana producer and distributor. The rapid increase in the incidence of chronic diseases and the need to reduce healthcare costs have led to the growth in telemedicine, which has companies racing to bring new products to market.
In this interview with The Life Sciences Report, Novick discusses a regenerative medicine company pursuing partnerships in Japan for its cell therapies to treat chronic tendinosis, damaged or aged skin, and pattern baldness. A small-cap American biotech has secured a patent agreement with a larger British firm, garnering the attention of three sector analysts.
With data from multiple studies due out this quarter, this biotech's RNA interference delivery platform has the potential to transform treatments for indications from cancer to ophthalmology, says Dr. Danny Deadlock, founder of Microcap. Jason McCarthy, an analyst at Maxim Group, discussed this France-based biotech firm's near-term clinical trial and catalysts.
The first approval of a cell therapy for treatment of pediatric blood cancer prompted H. Wainwright to increase its price target for a UK-based biotech manufacturing one of the therapy's components. Jason Kolbert, analyst with Maxim Group, assesses the billion-dollar transaction that would bring Kite Pharma and the earning potential of its cell therapy programs under the larger biotech's umbrella.
A licensed producer of medical cannabis in Canada will begin trading on the Canadian Securities Exchange on Aug. Analyst Ram Selvaraju with H. In an update on this company's clinical cell therapy programs targeting blood cancers and osteoarthritis in the knee, Gabrielle Zhou of Maxim Group describes progress that sets the stage for "value inflection.
A year-over-year increase in sales of its flagship product, and the prospect that its technology could be used to promote the efficacy of cell therapies, helped spur a target price increase on this biotech. Positive clinical data for this U. With the launch of its over-the-counter combination treatment for joint pain and new licensing agreements for feminine lubrication product Zestra, this San Diego-based company is expanding both its therapeutic and international reach.
Kenneth Ameduri, founder of Crush the Street, discusses why he believes now is a good time to take advantage of cannabis investing opportunities. A company with Canadian medical cannabis provider Aphria's backing is doing a reverse takeover on the Canadian Securities Exchange and expects to begin trading on July This is primarily due to the performance of a handful of companies that have been moving their assets farther down the development pipeline, according to the analysts who follow them.
A Vancouver-based biotech firm that aims to become the first preventative medicine company is expected to commence trading on the Canadian Securities Exchange July With enrollment complete in its Phase 3 trial of a compound that treats post-operative pain, and an infusion of cash from a new partnership with a major pharmaceutical corporation, one analyst has initiated coverage of this California-based company, and another has reiterated his investment thesis.
Now that the FDA has lifted its clinical hold on Phase 3 study of Inovio Pharmaceutical's immunotherapy for cervical dysplasia, three analysts are making note of what the progress means for both the company and investors. The potential of RXi Pharmaceuticals' sd-rxRNA technology in the development of cancer immunotherapies has resulted in an extension of its research collaboration with Oslo-based PCI Biotech and captured the attention of two analysts.
NASH is an epidemic in the U. Yet no FDA-approved treatments are available, with the exception of liver transplantation for end-stage disease. In part two of his interview with The Life Sciences Report , Ed Arce, managing director in equity research and senior analyst covering companies in the biopharmaceuticals and specialty pharmaceuticals sectors for H. Wainwright, and organizer of the recent inaugural NASH Investor Conference, says that small companies are rushing to fill the pipeline, with numerous compounds in trials.
In light of a decision to pull its application for approval of vosaroxin in the European Union, Sunesis Pharmaceuticals has designated its BTK inhibitor program targeting chronic lymphocytic leukemia as its new lead program. Inovio Pharmaceuticals' pipeline of vaccine and immunotherapeutic products is advancing steadily through the phases of development, with a host of milestones anticipated in , including the start of a Phase 3 trial in cervical dysplasia and the initiation of trials with partners in brain cancer and cancers caused by human papillomavirus.
Joseph Kim, walks investors through the promising possibilities, and also provides updates on its vaccines for the Zika, MERS and Ebola viruses. Up to one-third of Americans may have conditions that lead to NASH, yet the disease is far from a household name.
Closely linked with obesity, the disease does not become symptomatic until very late stage. Ed Arce, managing director in equity research and a senior analyst covering companies in the biopharmaceuticals and specialty pharmaceuticals sectors for H.
In part one of his interview with The Life Sciences Report, Arce discusses the disease, its market potential and how companies large and small are trying to fix the current dearth of treatments. How fast is my cancer progressing? Does this treatment present my best option for a cure?
These two big questions, which determine outcomes for patients with serious diseases such as Hodgkin's lymphoma, prostate cancer and Alzheimer's disease, are addressed by the platform technology in development by 3D Signatures Inc.
Kevin Little, describes the TeloView platform, its utility in the marketplace and what makes it a compelling investment.
With the impacts of Alzheimer's disease on patients, doctors and the health care industry expected to burgeon over the next decade, ProMIS Neurosciences has developed a preclinical program that targets the root cause of the disease, and also offers the potential to get in on an investment with a double bottom line, says Elliot Goldstein, CEO of ProMIS, in this interview with The Life Sciences Report.
Maxim Group noted that data from Zynerba's Phase 2 proof of concept trial will be released in the third quarter; positive data would set the stage for Phase 3 trials. Maxim Group recently initiated coverage of VistaGen Therapeutics, citing its progress on development of a fast-acting therapy to treat major depressive disorders. The Small-Cap Biotech Watchlist, composed of 20 companies targeting a range of indications including blood cancers and solid tumors, irritable bowel disease and orphan diseases, has posted a modest gain since the first of the year.
Positive results from RepliCel's Phase 1 trial for the treatment of aging and sun-damaged skin follow the release in the past few weeks of positive data from trials for chronic tendon problems and for hair loss. The 4th annual AlphaNorth Capital Conference brought together over 40 emerging growth companies with top investors. In this interview with Streetwise Reports, Steve Palmer, founder and president of AlphaNorth Asset Management and a co-organizer of the conference, discusses a diverse group of companies that were selected to attend the conference, including three biotech companies.
In this interview with The Life Sciences Report, Rahim provides his view of the sector and profiles four companies he believes may have great upside. Zynerba Pharmaceuticals specializes in developing and commercializing synthetic cannabinoid therapeutics formulated for transdermal delivery.
With a swab taken from the inside of a patient's cheek, 3D Signatures' TeloView platform has demonstrated its ability to diagnose Alzheimer's disease, and also to assess whether the disease is manifesting in a mild, moderate or severe form. The Tel Aviv-based company specializing in the development and commercialization of cannabinoid-based treatments has a drug for Tourette Syndrome in Phase 2a trials and is additionally developing a drug for mild cognitive impairment.
The IPO helps put it on a path to join much larger companies developing cannabinoid-based drugs. RepliCel's successful conclusion of its Phase 1 trial for hair loss sets it up for the next steps in the drug's development. Stellar Biotechnologies and Amaran Biotechnology have entered into an exclusive agreement where Stellar will supply KLH to the biopharmaceuticals manufacturer.
Several KLH-based vaccines are in trials for indications as varied as breast cancer and lupus, and clinical success could propel Stellar Biotechnologies, which is the only provider of KLH that has its own aquaculture facilities, says Jason McCarthy, an equity research analyst with Maxim Securities.
Donald Trump's presidency is a real nitro boost for the future of the biotech sector in the U. The stage has been set for high levels of uncertainly, and with uncertainty comes opportunities in commodities, posits Lior Gantz, editor of Wealth Research Group, who also sees opportunities in disruptive technologies in the medical arena.
RXi Pharmaceuticals' proprietary self-delivering RNAi sd-rxRNA platform offers efficient delivery to cells ex vivo, an application with tremendous potential in immuno-oncology. It's no surprise then that RXi has acquired MirImmune, a company that has been focusing on the next generation of immunotherapies for the treatment of cancer.
As Viveve Medical ramped up its U. Stocks in all areas of life sciences including biotech to pharma have been on a roller coaster since Donald Trump won the election in November. Wealth advisor Kristin McFarland discusses the big picture for pharmaceutical investment under the new administration. Regeneus, an Australian regenerative medicine company, has entered into a collaboration with a major Japanese firm to manufacture its stem cell therapy Progenza, a move that may accelerate approval and that has a pair of analysts optimistic about the company's future.
Veteran investor Bob Moriarty discusses Luminor Medical Technologies, whose Scout DS technology offers a noninvasive diabetic screen, measuring blood-sugar levels without taking blood. The cannabis industry attained new highs in , paving the way for some big changes this year, says Tom Beck, senior editor of Portfolio Wealth Global.
Inovio's Zika vaccine has demonstrated robust antigen-specific antibody responses in a Phase 1 study with 40 volunteers. Why should investors keep an eye on these twenty small-cap biotechs in ? Jason Napodano of BioNap Consulting takes an in-depth look at BrainStorm Cell Therapeutics, including the science, the Phase 2 data and the potential valuation of the company developing adult stem cell-based therapies for neurodegenerative diseases. Now in its fifth year, the Life Sciences Report Biotech Watchlist includes nineteen small-cap biotech companies selected by top analysts in the field, and will be presented at the Biotech Showcase in San Francisco in January.
The last several months have been active ones for Viveve: VistaGen Therapeutics has granted an exclusive sublicense for its stem cell technologies to BlueRock Therapeutics, a new biotech backed by pharma heavyweight Bayer AG and venture capital firm Versant Ventures of San Francisco. Technical analyst Clive Maund charts movements in the cannabis sector after the Nov.
Gecko Research discusses the bull market for marijuana, the road to legalization in Canada and why Emblem Corp. Reliq Health Technologies is initiating a trial of its remote patient monitoring system with The Feldman Institute in Louisiana, the fourth program for the company's innovative technology.
With the election now nearly a month old, and hot-button issues such as drug pricing still in the press, industry watchers have begun to weigh in on what might happen in the biotech and pharma markets when Trump takes office. By securing an exclusive option to acquire MirImmune Inc. Due to drug pricing controversies, there has been much concern about how the outcome of the upcoming election will affect pharmaceutical stocks. Rising healthcare costs continue to preoccupy providers, patients, politicians and investors.
Some cost increases stem from inefficiencies in the medical system, some from social and demographic trends, and others are a function of profit motives on the part of insurers and a few drug companies.
Private-pay aesthetic procedures constitute a trend in medical devices, according to Anthony Vendetti, Director of Research at Maxim Group. These nonreimbursable types of procedures have seen rapid growth in the past decade. In this interview with The Life Sciences Report, Vendetti discusses Viveve Medical, which is attempting to leapfrog the competition to get FDA approval to use its patented radiofrequency technology to improve women's sexual function.
Australian regenerative medicine company Regeneus Ltd. Bob Moriarty profiles Imagin Medical, a company that has developed a new way of detecting bladder cancer through endoscopes.
The late-stage biopharmaceutical company Soligenix has had a string of good news. This, according to Maxim Group analyst Jason Kolbert, will help the company determine an "optimal" strategy for intradermal skin vaccination. Radioimmunotherapy is experiencing a renaissance, and Actinium Pharmaceuticals Inc. With two assets targeting treatment of AML in older adults in clinical trials, and a platform primed to "nuke cancer," the company has a number of milestones in its near future that investors should be watching.
Concerned about investing in the life sciences in the United States, where markets have slumped in and the presidential election furthers volatility? With its lead drug candidate apabetalone already in Phase 3 targeting major adverse cardiac events, Resverlogix has expanded its scope by initiating a Phase 1 study of the small molecule to further investigate its potential applications.
Oxycodone is a powerful and lucrative painkiller, but one with serious downsides. Dependency on the opioid has become a major issue medically, politically and, most profoundly, for the patients whose addictions have become debilitating or fatal. In tandem with the broader markets, the biotech indices reeled on the news of Britain's vote to exit the European Union.
Given the uncertainty and dire economic forecasts, The Life Sciences Report has reviewed commentary from sector experts and biotech publications to help investors understand what Brexit might mean for the industry.
With blockbuster indications like cancer, lupus and Alzheimer's disease being targeted by partners, and a manufacturing process sure to satisfy regulators, McCarthy lays out a value proposition for Stellar's KLH that investors should not ignore. After decades of disappointment, cell therapies and gene therapies are finally seeing light at the end of the tunnel. Investors, investigators, clinicians, and patients with serious unmet needs are watching pivotal trials move into the home stretch.
Cancer patients often receive multiple rounds of chemotherapy, with new drugs incorporated into treatment programs as tumors develop resistance. OncoSec Medical Incorporated's Punit Dhillon describes how his company is challenging that paradigm with a proprietary platform that delivers therapeutic agents directly to the tumor, while also laying a foundation for expanded use of combination immunotherapies at the forefront of cancer treatment.
Managing both acquisitions and internal growth at the same time is difficult for most small companies, akin to drinking water and singing at the same time. Not so for Nobilis Health Corp. The conductor is merger-and-acquisition specialist Kolin Ozonian, who brings years of business development experience in large-cap healthcare to this small-cap enterprise. In this interview with The Life Sciences Report , Ozonian discusses his company's newest technology and talks about how Nobilis will achieve critical mass.
Recent news from Inovio Pharmaceuticals Inc. Biotech and medtech startups are not confined to the U. Unmet medical needs exist all over the globe, and they create a powerful vacuum that sucks in bright minds and risk-taking capitalists.
Australia is a good example: The regulatory environment supports first-in-human experimentation and entrepreneurship. Healthcare Analyst Dennis Hulme of Edison Investment Research is headquartered in Sydney, and in this interview with The Life Sciences Report , he cites a group of Australian medtech and biotech names that investors should look at very carefully. Opioid abuse has moved front and center in the political and social arena, sparked in recent weeks by the still-unexplained death of music legend Prince.
Heroin is the headline, but addiction to prescription painkillers, like those reportedly used by the pop icon to control chronic pain, runs a close second. How can the biotech industry deter abuse of drugs like oxycodone? Intellipharmaceutics International has a potential solution, Chief Financial Officer Domenic Della Penna tells The Life Sciences Report , as well as a robust pipeline of generic options for a variety of indications.
Exosome Sciences, a majority-owned subsidiary of Aethlon Medical Inc. In this interview with The Life Sciences Report , Executive Chairman James "Jim" Joyce shares the initial clinical results of a biomarker study to diagnose chronic traumatic encephalopathy CTE , a neurodegenerative disorder often found in professional football players through postmortem autopsy.
Exosome Sciences believes its TauSome test may be the first noninvasive candidate to diagnose CTE in living individuals. The company has several active clinical programs, led by bertilimumab, a first-in-class, fully human IgG4 monoclonal antibody, which is currently in Phase 2 clinical trials for the treatment of inflammatory bowel disease and skin disorders. Immune Pharma also has a growing presence in immuno-oncology, with the goal to create a fully sustained oncology subsidiary in the near future.
In this article for The Life Sciences Report, analyst Jason Napodano digs into the company's pipeline and investment potential. ROTH Capital Partners' Joseph Pantginis falls into that old-fashioned category of analysts who believe that good data can't help but drive a stock, no matter how far into the depths it may have sunk. In this interview with The Life Sciences Report , Pantginis presents his detailed growth theory on two names, and he leaves two Focus Picks on the table for investors to do further diligence on.
With a robust pipeline of drugs in late-stage clinical trials and milestones on the horizon, it's no wonder Soligenix Inc. Christopher Schaber, holds an optimistic view of the company's future. Schaber expands on the status of the company's portfolio. Solid tumors are typically managed with surgical resection, chemotherapy, radiation and biologics, but it's the secondary tumor mass, the metastasis, that kills patients.
Holden describes an essential target in aggressive prostate cancers, and a drug with the potential to address that target and extend the lives of thousands of men. To treat chronic pain without risk of addiction is to straddle a knife's edge. But Relmada Therapeutics Inc. In this interview with The Life Sciences Report , Relmada's Michael Becker describes the company's programs, which are advancing steadily toward the marketplace.
While the vagaries of the political season create uncertainty in the biotech and pharmaceutical sectors, companies are moving ahead with innovative cell therapies, gene therapies and new, safer ways to deliver addictive drugs, and investors find themselves in a position to play the development ideas with varying degrees of risk.
In this interview with The Life Sciences Report , George Zavoico of Jones Trading Institutional Services explores how the presidential race could affect the biotech industry, and explains the growth prospects of three biotech names that could strike gold.
Data can create or destroy the value of a biotech investment in an instant, but hitting or missing an endpoint doesn't always tell the story. It took patience, time, additional capital and careful analysis of subpopulations of breast cancer patients to figure out that Herceptin would ultimately save many lives. In this interview with The Life Sciences Report , George Zavoico of JonesTrading Institutional Services discusses the growth prospects of three biotech names that have been wrecked and left for dead, but could ultimately resurrect themselves from a misleading pile of rubble.
Frank Oakes, the chairman, president and CEO of Stellar Biotechnologies, has a passion for the potential life-saving cures the ocean may provide. His company, a world leader in the production of sustainable, scalable and fully traceable GMP-grade KLH protein, has established research and manufacturing facilities along the Pacific Ocean to produce KLH, and Oakes himself has more than three decades of management experience in aquaculture.
In this interview with The Life Sciences Report , Oakes talks about how he got involved in this exciting and emerging space, and describes the potential Stellar KLH has in the burgeoning field of immunotherapy. It takes extraordinary dexterity to execute a strategic merger, and then to take first steps toward positioning a new molecular entity for a Phase 3 drug trial and potential partnership with a big pharma.
That's exactly the inflection point at which Diffusion Pharmaceuticals Inc. In this interview with The Life Sciences Report , Kalergis lays out Diffusion's plan for pivotal development of its treatment for primary brain cancer, which could drive the company's market cap to valuations that would bring huge upside to investors if successful. Lisa Crossley, describes the company's comprehensive hardware and software solution, dubbed CareKit, which allows patients to receive high-quality care in the home, improving health outcomes and enhancing quality of life for patients and families while reducing the cost of care.
According to newsletter writer Chen Lin, this is a huge binary event for the company. In this article, Lin lays out his investment thesis on the stock ahead of the meeting, and his hopes for eteplirsen's approval. Nobilis scans the market for clinics that can be acquired and scaled up using sophisticated direct marketing approaches. In this interview with The Life Sciences Report , Nobilis' mergers-and-acquisitions specialist Kolin Ozonian talks about the business model and tells investors how he and the Nobilis team plan to aggressively grow the company.
OTCMKTS , a small-cap biotech company focused on developing novel compounds for a range of applications, has released a flurry of announcements over the past five weeks as several of its pipeline drugs cleared regulatory hurdles and readied for their next milestones. After a devastating start to , biotech stocks have snapped back.
In the meantime, Molloy says, individual and small institutional investors can still buy growth stories at bargain prices.
In this interview with The Life Sciences Report , Molloy mentions three names with near-term catalysts that, with good data, can bring a needed lift to biotech portfolios. The Life Sciences Report's Small-Cap Biotech Watchlist was not immune to that movement, heading into negative territory almost from the moment the selected companies were introduced.
But as the market has shown signs of rebounding, so too has the Watchlist. Eden Rahim of Toronto-based Next Edge Capital has had his share of multibagger and grand-slam successes, and is one of the few mutual fund managers who feels comfortable investing in micro-cap biotech names side-by-side with billion-dollar biotech stocks.
In this interview with The Life Sciences Report , Rahim describes a group of micro-, small- and mid-cap biotech names possessing powerful growth drivers that could perform even when the overall market is not so hot. Continuing stock market volatility is causing some investors to rethink their biotech investments. For generalists, in particular, choosing a winning company is almost a roll of the dice. Stock analysts fall into a few different categories. There are buyside analysts and sellside analysts, and then there are independent analysts commissioned by companies to highlight underexposed business models and growth prospects.
The independent analyst, such as Van Leeuwenhoeck's Marcel Wijma, normally works in the small- and micro-cap stock universe, where the buyside and sellside rarely go. In this interview with The Life Sciences Report , Wijma brings to light five diverse, overlooked small-cap biotech stocks from Canada, Europe and Australia that could bring huge returns to investor portfolios.
Patients on dialysis and cancer patients with indwelling catheters live with the possibility of contracting drug-resistant infections that can become more life threatening than their primary diseases. MKT is developing a platform that has shown impressive results in preventing serious bloodstream infections. Chief Scientific Officer and Cofounder Antony Pfaffle, an internist who practiced nephrology, joins the conversation to relate his experience managing chronically ill patients undergoing catheter-based therapies in the critical care setting.
It takes nerves of steel to follow micro-cap stocks and ascribe future valuations in hefty multiples. In this interview with The Life Sciences Report , Selvaraju, a former big pharma researcher, details four growth names that could follow in the hallowed footsteps of previous winners.
Cynata Therapeutics of Australia has carved a technological niche in the fast-advancing cell therapy market with a platform that renders the production of stem cell-based treatments for cancer and diseases of the immune system easy and affordable, saving lives and money. In this interview, Cynata's executive chairman Stewart Washer tells The Life Sciences Report why his company's technology, in studies for graft-versus-host disease, has proven itself a profit driver.
Canada is a wellspring for natural resources and the industries built around them. But the country also encompasses healthcare-related businesses that are growing, generating cash flow and flourishing. As a hedge fund and mutual fund manager concentrating on Canadian companies, he has made a specialty in acquisitions of cash-generating healthcare companies.
In this interview with The Life Sciences Report , Campbell discusses seven small-cap growth names, all of which have reached share-price levels that do not reflect their capacity to grow. Some may offer rare opportunities to buy at risk-mitigated value prices. Drug development seems to move at a snail's pace, but Cellceutix Corp. Ehrlich and Chief Medical Officer Dr. Daniel Jorgensen, an infectious disease specialist, discuss the candidates, beginning with the first new class of antibiotics to enter Phase 3 in skin infections in decades.
Sometimes wonderful ideas live on and create value for the ages. This may prove a challenging year for small-cap biotechs, but the five analysts who selected companies for inclusion on The Life Sciences Report's Small-Cap Biotech Watchlist believe these companies have a good shot at producing innovative products in a variety of indications and producing value for investors.
Discovery, it turns out, is not just about finding the cure for a particular disease; it's also about finding the companies best poised to reach that goal. Combining academic discipline with methodical due diligence, Alan Leong of BioWatch News undertakes a regimented review of each biotech and medtech stock he investigates. In some cases he will follow a company's clinical development program and data for years before he pulls the trigger and recommends a name.
In this interview with The Life Sciences Report , Leong presents a number of names for investors' consideration. Many won't be mentioned in his usual write-ups: It's an early look at what's on his watch list and in his inbox. Each company carries its own risks, but every stock has a special growth story that could propel huge gains if data fall into place. The new year is off to a turbulent start, with indices across all markets, including biotech, sliding downward in the face of headwinds from China.
Canadian healthcare stocks offer a windbreak for biotech investors, however, especially if they select a diversified basket across the various sectors. There is no cure for ALS, a debilitating and ultimately fatal neurological disease. BrainStorm made the credibility-building announcement on the opening day of major biotech conferences in San Francisco.
Targeting diseases from inside the cell could be medicine's version of the dawn of the Internet. Or, as newsletter writer Chen Lin describes it, advances from companies like Sorrento Therapeutics Inc. The traditional biotech investor wants to hit the lottery with a blockbuster molecule, but there are less risky avenues to profit, where capital is deployed to leverage the healthcare market via reimbursement from Medicare, the Affordable Care Act and private-pay insurance.
In this interview with The Life Sciences Report , Russell Stanley of Mackie Research Capital tells investors that growth is where you find it, including in acquisitions. NASDAQ , is pioneering the potential use of an exosome-based biomarker to diagnose chronic traumatic encephalopathy CTE , a condition that otherwise can only be identified postmortem. As James "Jim" Joyce, executive chairman, tells The Life Sciences Report , other companies are exploring this approach in oncology, but Exosome Sciences is the only company advancing an exosome-based candidate to diagnose CTE.
The merger of RestorGenex Corp. The combined company will be named Diffusion Pharmaceuticals Inc. Before starting his own firm in July, Jason Napodano spent more than 12 years at Zacks Investment Research producing highly detailed small-cap biotechnology research.
Today, as owner and senior analyst at BioNap Consulting, Napodano is doing much the same, but with more flexibility. He follows dozens of companies and continues to perform diligence on new names with the single goal of finding multibaggers. One of his themes is to take a biotech basket-of-stocks approach, since he knows some names will fail but the winners will move upward with momentum. In this interview with The Life Sciences Report , Napodano discusses small-cap names with the potential to power portfolios to extraordinary levels.
In this interview with The Life Sciences Report , Gengos discusses his firm's recently reported Phase 2 data in glioblastoma, as well as the company's strategy for the upcoming registration trial.
In advance of the Biotech Showcase , The Life Sciences Report has once again solicited top analysts to provide the names of innovative biotech companies that investors should keep an eye on in the upcoming year. Why have stem cell and regenerative medicine companies underperformed other segments of biotech? Maxim Group's Jason Kolbert and Dr. Jason McCarthy identify a possible answer: Investors believe stem cell data has yet to definitively reach proof of concept in the blockbuster indications that the companies are pursuing.
In this interview with The Life Sciences Report , Kolbert and McCarthy tackle the issues that have frustrated investors, and leave readers with a list of names that could reap multiples on investment while patients enjoy longer lives. This fall, presidential candidate Hillary Clinton once again proposed price caps on out-of-pocket payments for pharmaceuticals. Liana Moussatos of Wedbush Securities has followed the price-cap discussion since the s, and says the issue is more political than real.
Given that, she tells The Life Sciences Report about some up-and-coming companies with products she believes are likely to make big improvements in the health of patients and the wallets of investors. Several controversies have taken the air out of drug and biotech stocks, which performed quite well until midsummer. Among the injured players are generic drug makers, which landed hard after a high-flying period. In this interview with The Life Sciences Report , the analyst identifies a handful of select generic drug and specialty pharma stocks that still have pricing power and margin expansion potential.
Interventional radiology has been described as the surgery of the new millennium by Stanford Healthcare, offering less invasive procedures, more precise placement of catheters and, often, fewer complications for patients and higher throughput for healthcare facilities. Robotics is making this new area of medicine possible.
In this interview with The Life Sciences Report , Dushyanth focuses on four small- and micro-cap specialty pharma and device names with engineering tie-ins, and she expects all to produce exciting results for investors. Reni Benjamin of Raymond James has watched biotechnology move into a new era in which cells and genes can be manipulated to produce true disease-modifying results. In this interview with The Life Sciences Report , Benjamin outlines the groundbreaking work being done by a number of companies with the potential to return multiples on investment over the next two to three years.
Skin disorders encompass a broad class of medical indications, from psoriasis to melanoma. Many companies focus on developing treatments for specific dermatological indications, but few have been able to build product portfolios with the range of therapeutic and consumer products currently marketed by Cipher Pharmaceuticals. SeeThruEquity's Ajay Tandon and Jay Albany are riding the biotech bull by harnessing the huge upside potential of micro-cap companies working in multiple subsectors, particularly in the rapidly advancing cancer immunotherapy sector.
In this interview with The Life Sciences Report, Tandon and Albany toss the names of several companies into the arena for investors' consideration. Now this broad-spectrum platform is being tested against cancer and other life-threatening diseases. A strategy of over-the-counter sales helps derisk Nutra Pharma Corp.
Chronic inflammation causes long-term pain and tissue scarring, manifesting in a range of diseases from rheumatoid arthritis to liver cirrhosis. With the introduction of gene therapy and immunotherapeutics, novel strategies targeting inflammatory disorders are being developed, creating hope for patients with no other clinical options.
Recent stock market volatility is an opportunity for biotech investors to pick up great stocks before market caps rise substantially. Stem cell therapies have been slowed by high production costs, batch-to-batch variability and limited seed material.
Ross Macdonald, CEO of Cynata Therapeutics, tells The Life Sciences Report how his company's innovative manufacturing methods can generate robust, consistent and inexpensive stem cells, and how this technology is likely to accelerate the commercialization of stem cell therapies worldwide.
In a volatile macroeconomic world, micro caps can offer some immunity as they move based on company news rather than front page headlines. But you have to pick your companies carefully. Regenerative medicine through stem cell technology is a source of hope for many suffering from ailments including Alzheimer's disease, diabetes, spinal cord injury and cancer.
While new therapeutic options are continually in development, progress has, until recently, been hampered by political and medical ethics arguments.
Because of patient advocacy, new technologies are now advancing, from development of an artificial pancreas to the hope of culturing intact human organs. In this interview with The Life Sciences Report , Bernie Siegel, founder and executive director of the Genetics Policy Institute, describes recent progress and developments in the regenerative medicine universe.
Growth in company valuations has outpaced sales for several years, but the coming weeks will see rapid fluctuations as the two begin to realign.
In this interview, Singh shares his predictions for the rest of with The Life Sciences Report , and identifies several companies to hold for potentially big returns. Immuno-oncology has the potential to not only transform medicine, but also to become a multibillion-dollar market for a drug developer with the right team and the right compound. Maxim Group Equity Analyst Jason McCarthy has developed a biotechnology theme that leverages immunotherapy platforms serving both cancer and infectious disease indications.
It's an elegant dual premise that enables one side to fund development of the other, and it seems to be working beautifully for companies and their shareholders. In this interview with The Life Sciences Report , McCarthy explains the principle and describes five companies proving up the model's profitability. It's all about data for John McCamant and Jay Silverman of the Medical Technology Stock Letter , and right now it's festival time as we approach the busy season of market-moving catalysts and milestones.
From now until December, biotech investors will be focused on the press releases, webinars and scientific presentations that serve as a vitality tonic for the entire biotech industry. In this interview with The Life Sciences Report , McCamant and Silverman give a detailed picture of their growth theories on six biotech stocks that could reap many multiples on invested capital over the next few years.
With the markets in whiplash mode, Joe McAlinden, founder of McAlinden Research Partners and former chief global strategist with Morgan Stanley Investment Management, believes volatility is going to stick around for a while. In fact, he just announced that we might see a correction double of what we've had so far.
In this interview with Streetwise Reports , McAlinden bucks conventional wisdom and lays out his investing strategy for this period of market uncertainty. The growing need for recombinant proteins for vaccines and therapeutics is causing the biotech industry to look beyond vat fermentation and cell cultures for protein expression systems that, like iBio Inc.
Bob Erwin describes the iBioLaunch technology and what it offers to drug developers and investors. CAR T-cell therapies show amazing potential in treating blood cancers, but there's a lot of work to do before the cells are ready for commercialization. He also describes the reality behind the growing excitement in regenerative medicine, and what investors should know about some very innovative, but often overlooked, small companies.
Ran Nussbaum, managing partner with The Pontifax Group, doesn't worry too much about overall market volatility. Biotechs, he feels, are somewhat immune to turmoil because their fundamentals are based in real life. He prefers to play on good science and unmet medical needs, and then sit tight until a stock is discovered.
In this interview with The Life Sciences Report , Nussbaum describes a few takeover candidates primed for stellar growth, as well as promising names that are part of the movement toward personalized medicine. The evidence is mounting: In the past five years, development of new therapies has aimed for true disease modification and actual cures. Many novel ideas are now in the clinic, and have opened up fresh opportunities for dramatic industry growth, especially in the gene and cellular therapy realm.
In this interview with The Life Sciences Report , David Nierengarten of Wedbush Securities brings a handful of select names to investors' attention, including a couple of companies with technologies that could revolutionize medicine. Small-cap life science investors in the U. In Canada the focus is a bit different.
Bruce Campbell of StoneCastle Investment Management has made a killing over the past year on rather unadventurous healthcare companies that have been acquiring smaller businesses and growing outward by fixing spokes to a hub.
In this interview with The Life Sciences Report , Campbell describes five small-cap growth stories poised to ring up more acquisitions, more cash flow and more share price appreciation to portfolios.
Volatility is the nature of the biotech beast, and it must be tamed or utilized to advantage. That's the philosophy of Eden Rahim, portfolio manager and option strategist at Theta Strategies Capital. Can you grow a portfolio if some of your more successful names are called away by option buyers before the stock goes into the stratosphere? The answer is yes, and in this interview with The Life Sciences Report , Rahim describes his technique and leaves readers with six names that he fully expects to reap very large gains.
Regenerative medicine is surging toward the mainstream, and Athersys Inc. Potential safety concerns surrounding cell therapies have been largely addressed, and now the efficacy of the company's MultiStem platform in several massive markets, including stroke, heart attack and acute pulmonary disease, are ready to be tested. Regenerative medicine is just beginning to be understood by governments and investors alike. Last autumn, new regulations took effect in Japan that promise to speed patient access to some of these new therapies.
Medical technology is not considered a huge-margin investment in the way that the biotech and drug industries are. However, some of today's medtech blurs the line, including hybrid companies developing stem cell and drug-device delivery systems that address complex disease indications ranging from blindness to spinal paralysis.
Caroline Corner of Cantor Fitzgerald follows companies with technologies that can both address dire diseases and reap windfalls for investors.
In this interview with The Life Sciences Report , Corner brings important names to investors' attention. Investors who lament missing the U. Biotech valuations in Australia are not in sync with U. Direct-acting antiviral therapies are poised to become a major disruptive technology in treatment for viruses, including human rhinovirus and human papillomavirus. Revenue and earnings at the big biotechs are signaling investors that the market is still strong, and that there is still a huge thirst for early-stage devices, small molecules, biologics and cellular therapies.
In this interview with The Life Sciences Report , Napodano details the upside for small-cap biotech names that he believes will be huge gainers for investor portfolios. The life sciences industry is evolving rapidly. Many say it's at the beginning of an explosive growth stage that will see the development and commercialization of novel therapeutics and diagnostics still being imagined in scientific laboratories today.
This explosion of innovation also means an explosion of investment opportunity. In this interview with The Life Sciences Report , Marcel Wijma, chief research analyst at Van Leeuwenhoeck Institute, explores some smaller companies working on the industry's forefront. What a difference just nine months can make. Ramin "Ron" Najafi talks about the turnaround and how he is steering the product portfolio toward a hockey-stick sales growth curve.
Biotech investors are abuzz over immune checkpoint inhibitors and T-cell therapies, but which ones do you pick? JonesTrading Institutional Services Senior Equity Analyst George Zavoico is moving rapidly to initiate coverage on some key names in this space, and is casting a wide net in hopes of catching winners. In this interview with The Life Sciences Report , Zavoico delineates some movers and shakers in the cancer immunotherapy field, and recommends investors keep their pencils sharp and eyes open as data emerge over the next year or two.
The list of problems with investing in micro-cap biotech stocks begins with extreme volatility and lack of liquidity and ends with the inability to get validation from sophisticated investors who are unable to own such small companies. Nevertheless, sift through the pile and investors can find gems. Joseph Pantginis of ROTH Capital Partners recognizes the characteristics that make some of these tiny companies move up the ladder in market valuation.
In this interview with The Life Sciences Report , Pantginis discusses five names with development programs capable of generating dramatic growth.
Analyst Pooya Hemami of Edison Investment Research casts a wide net when it comes to investment opportunities in the life sciences. You name it, his universe includes it: Hemami reflects on the biotech market at midyear, and describes a robust basket of outstanding companies with pipeline treasures. Chen Lin produces a monthly scorecard that tracks the performance of the stocks in which he invests.
Every month, he reveals how he is doing in his newsletter, What Is Chen Buying? What is Chen Selling? In this interview with The Life Sciences Report , Lin identifies undervalued companies with paradigm-shattering pipeline products that could turn small change into big profits.
Geert Cauwenbergh tells The Life Sciences Report about the transformational treatments RXi Pharmaceuticals Corporation has in the pipeline, therapies that can both enrich lives and investors' portfolios. Steve Brozak sees a bubble getting larger, and he is anticipating the time when biotech stocks pull back to take a breather, like all high-flying markets ultimately do. While investors may own innovative companies with highly disruptive technologies, Brozak insists on careful diligence to find names with the potential for explosive growth and avoid the disappearing acts.
In this interview with The Life Sciences Report , Brozak, president and managing partner at WBB Securities, showcases six names with strong immunotherapeutic platforms that he believes have extraordinary potential to reward investors many times over. Nobody understands the ins and outs of the antivirals better than the CEO of ContraVir Pharmaceuticals, and James Sapirstein unfolds the backstory behind the creation of his newest venture in this interview with The Life Sciences Report.
Investing in micro- and small-cap biotech companies carries great risk, but for investors who take the time to dig out the value proposition, the upside can be phenomenal.
Enter Ross Silver of Vista Partners, who publishes research and owns many of the stocks he writes about. In this interview with The Life Sciences Report , Silver puts two biotech names on the table for investors to consider. An Israeli biotech is hard at work on a new treatment for neurodegenerative disease that holds promise in a variety of devastating diseases and enjoys fast-track and orphan drug status in its lead indication, amyotrophic lateral sclerosis ALS.
Tony Fiorino, the U. The year is off to a bumpy start, though the rough ride is not predicated, necessarily, on individual company performance. An immunotherapy revolution is rocking biotechnology, and investors are searching for just the right way to play the new trend. Do you go with an unknown company where the upside could be unparalleled?
Do you go with an older name that has established partnerships with major pharmas? John McCamant, editor of the Medical Technology Stock Letter, has performed some serious diligence, and tells The Life Sciences Report about a handful of names with a range of market caps and the potential to achieve significant investment upside. Portfolio manager Bruce Campbell wants the best of both worlds in his Canadian healthcare investments.
He looks for companies that are strong and balanced, with muscular organic growth on one side and healthy acquisitions on the other. In this interview with The Life Sciences Report , the founder and president of Canada-based StoneCastle Investment Management spotlights six names that have proven themselves with good runs but have potential for much bigger gains. Stem cell research is controversial, little understood by both the public and the legislators who set the framework governing it.
In this interview with The Life Sciences Report , Tory Williams of the Alabama Institute of Medicine describes how her patient advocacy group is working with research institutes to advance stem cell science and provide the early-stage funding and contacts that researchers and young companies need to grow and prosper.
Drug discovery and development has gotten harder and more expensive, but the advances and technologies that whipped the market into a frenzy 15 years ago finally appear to be bearing fruit. There's a new kind of incubator in town. It's a gallery whose art is books, specifically illustrated books, often but not only those for children. It's also a prime venue for author signings, and they get some pretty stellar names.
Often working in conjunction with the Aero Theatre across the street, Every Picture offers an intimate environment for book lovers to get up close and personal with their favorite authors. The Beverly Hills Municipal Courthouse might be famous only because of people like Lindsay Lohan, but there's a better reason it deserves some love. Past the metal detectors, to the left of the marriage-license booth, stands an unassuming little wedding chapel, with a resident judge who marries couples every 15 minutes.
Rumor has it that's where Roman Polanski and Sharon Tate tied the knot. And as anyone who's planned a wedding knows, the event means just one thing — spending money. Whether it's hiring a florist, photographer, planner or DJ, the cost of today's weddings can be obnoxious, to say the least. But thanks to civil spots like the Beverly Hills Courthouse, the cost of the ceremony can help keep things under budget.
Plus, there's a fake quilted wedding cake, two imitation bouquets on loan, and the courthouse is right next to the picturesque Civic Center — all of which provide plenty of Kodak moments for the ol' wedding album.
Once you've come to accept — even embrace! For the price of one and a half Patron shots, you can fade into a sweet three-tub rotation of jacuzzi, tea bath, cold rinse, repeat. It's quiet, light and pretty, almost utilitarian at times — as if a lovely cleanse were a necessity, and a right. Every mini-mall east of La Brea Avenue has one: Budget basic decor — small Buddha shrine, desktop fountain, photo of a sun-drenched Thai beach — often matches the ho-hum massage.
And there's a super deal: Be prepared for an up-close-and-personal massage: A demure lady will knee your ass therapeutically as you lie on a cushioned mat on the floor half-naked. Almost invariably a she, except when it is Jack's strong fingers that stretch you. The fabric dividers between alcoves let the snores of others drift through; yours may soon join in.
Don't embarrass yourself by asking for a happy ending. You will be happy. No accreditation, no degrees, no pay, no tuition — the only thing you have to shell out for is your drinks. Run out of the top floor of the Mountain Bar, Chinatown's legendary Mountain School of Arts attracts a special variety of students, mostly from Europe, who want to come to Los Angeles to study, but perhaps aren't as interested in the credentials and limitations of the professional programs on the other side of downtown.
They intended MSA to be a new model for the L. The founders are very careful to correct you if you call it an alternative, as MSA sees itself not as an alternative but an equal to its more traditional competitors. Except for the teachers and founders buying their guests drinks, the school is run without cost with help from volunteers myself included , and still manages to get some of the best artists and curators in the city and abroad, from artists Paul McCarthy and Thomas Demand to international curator Hans Ulrich Obrist.
House of Intuition proprietress Marlene Vargas took one look at me and placed a shard of serpentine in my hand. You'd be hard-pressed to find a metaphysical center more genuine than this Eastside oasis, which Vargas rightly describes as a "spiritual detox center" for the seeker and the cynic alike.
You can simply enjoy one of 25 varieties of tea in the sunlit tea room, or work toward your Reiki certification, have your aura cleansed and get your chakras balanced. Offering tarot, past life, I Ching and astrological readings, crystal healing, psychometry and a host of other services and classes, the staff and the stock are handpicked, the medicinal remedies and incense hand-blended. A series of divine synchronicities coalesced to bring this magic place into being, and you can feel it.
Vargas, who offers crystal readings, says we all have our own intuition. If any youngish artist of talent had a hankering to go to grad school and more or less get himself perched on the first rung of being a "professional artist," I'd tell him to go to the Roski School at USC. Run with great aplomb these last years by Charlie White, USC's grad art program, with its special mix of incredible professors Frances Stark, Andrea Zittel, Judd Fine, Sharon Lockhart , and of course the fact that it's more or less fully funded to attend, has in these last years minted more commercially successful artists than the rest of the art schools combined.
For all the benefits of an MFA but without the ritual spanking of a critique, one can attend the Roski School's many excellent free lectures almost every Wednesday and Thursday during the school year. Jung Institute of Los Angeles , who assures me that I don't have to be a Jungian analyst-in-training to visit this highly specialized collection of more than 6, volumes on analytical psychology, mythology, religion, symbolism, anthropology, art, sociology and magic.
Jung looked for what made us work from the inside.
Category Archives: Weed Knowledge
elimination half-life of THC is about 7 days, and complete elimination of a single dose .. Safety and Efficacy of Medical Cannabis Oil for Behavioral and Psychological .. directly related to the degree of anaplasia and grade of tumor. Cannabinoids and their derivatives have been used for years in folk. A cannabis health and education center for anyone interested in medical marijuana. And through this less restrictive concept, allow them to live a healthier The folks behind marijuana-based rehab understand its importance more than most. guide for understanding the differences between hemp- derived CBD oils. WBC Champion boxer, cannabis advocate, and friend of Dixie, Ava Knight, are dedicated to living healthy and active lifestyles with cannabis and hemp. . Now that the laws have changed, Hancock believes that it's unjust to still . Get your dose of nutritious hemp seed oil while you're at work, at home or.